Hosted by EMJ · 🇺🇸 US · EN · 321 episodes
Established thought leaders with verified media credentials.
Join the EMJ GOLD team for a weekly exploration of all things pharma, featuring thought-provoking conversations, insightful interviews with high-profile industry guests and discussions about the latest trends and innovations taking the pharmaceutical sphere by storm.Whether its marketing, medical affairs, the use of digital techniques to create patient-centric approaches or something in between, there's something here for anyone interested in the pharmaceutical industry.
EMJ hosts EMJ GOLD: Pharma news, views and analysis, a business show with 321 episodes published.
This content has been funded by Angelini Pharma . In this episode, Isabel sits down with Rafal Kaminski, Chief Scientific Officer, Angelini Pharma, to explore how new science is reshaping brain health and what that means
In the final episode, the focus turns to prevention. Rachel Buckley examines whether Alzheimer's strategies should be sex-specific, the timing of interventions, and how lifestyle factors like physical activity contribute
This episode explores how reproductive ageing and biological sex influence Alzheimer's disease risk. Rachel Buckley discusses menopause, hormonal changes, genetic factors such as the X chromosome, and emerging evidence s
In the final episode of this series, Leslie Cho focuses on prevention. From lifestyle interventions and pregnancy-related risk to menopause, brain health, and cholesterol management, she shares practical strategies clini
Why does cardiovascular data so often fail women? In Part 2, Leslie Cho unpacks how trial design, symptom bias, and underdiagnosis of microvascular disease distort care for women, and what the evidence actually tells us
In Part 2 of the 2026 pharma forecast, the guests discuss the biggest unknowns for the year ahead and share a personal goal they're working towards in 2026. Speaker bios Dheepa Chari Vice President and Head of Global Sci
As 2026 gets underway, healthcare and life sciences face a year of both promise and pressure, with investment, innovation and equity all in sharp focus. In Part 1 of this year's pharma forecast, four leaders explore wher
This week, Isabel brings together three expert voices for an end-of-year round-up, reflecting on the moments that shaped healthcare and life sciences in 2025. Joined by Jonathan Sackier, Chairman, Medical Advisory Board,
In Part 3, Carol Pitcher-Towner, Alnylam Pharmaceuticals, explores how the pharmaceutical industry can become part of the solution. She highlights why leadership diversity matters, how trial design still excludes too man
In Part 2, Carol Pitcher-Towner, Alnylam Pharmaceuticals, breaks down the systemic forces driving inequity, from diagnostic bias to the lack of women in key specialties like cardiology, and explains how historical clinic
This week, Isabel sits down with Carol Pitcher-Towner, Senior Vice President and Head of Development Programmes, Alnylam Pharmaceuticals, to unpack the gender inequities that continue to tarnish modern healthcare. Togeth
In Part 3, Hanna Svanbäck discusses the future of Alzheimer's care over the next five to 10 years, how trial design could be improved and reveals her opinion on the most exciting healthcare innovation on the horizon. Spe
In Part 2, Hanna Svanbäck discusses the latest and most significant innovations in Alzheimer's care. She also considers whether healthcare systems are prepared for the anticipated surge in cases, and shares some positive
This week, Isabel sits down with Hanna Svanbäck, Executive Director for Neuroscience, Eli Lilly, for an insightful discussion on the evolving landscape of Alzheimer's research. Together, they explore the latest breakthro
In Part 3 of the conversation, Giuseppe Savoja, Western Europe Senior Business Director, Cardiac Surgery Business at Medtronic, talks about his outlook for the future of his field, his views on how the industry and clini
In Part 2 of the conversation, Giuseppe Savoja, Western Europe Senior Business Director, Cardiac Surgery Business, Medtronic, shares how ECMO has transformed over the decades and explores how clinicians and industry can
This week, Isabel is joined by Giuseppe Savoja, Western Europe Senior Business Director, Cardiac Surgery Business at Medtronic, for a deep-dive into the evolution and future of ECMO, innovation in critical care and the r
In Part 2 of this conversation, Robert Stewart, CEO, Theramex, explains how wider society can improve outcomes for women and reflects on the impact of decades of neglect in the field. Speaker bio Robert Stewart is CEO of
The EMJ GOLD podcast returns. To launch the series, Isabel is joined by Robert Stewart, CEO, Theramex – a global pharmaceutical company solely dedicated to women's health. In Part 1 of this discussion, they unpack what i
Tune in as Isabel and Jade analyse the standout moments from EMJ GOLD's guests this season, uncovering the challenges and opportunities shaping today's pharmaceutical industry. From self-advocacy at work and the future o
Sponsor detection runs nightly. Check back soon.
No public pitch examples yet for this show.
Generate your own personalised pitchBased on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:
Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.
Shows with the most semantically similar episode content. Pitch one, pitch all; producers cluster.
EMJ GOLD: Pharma news, views and analysis has a verified contact on file. Create a free PitchCentric account to access it and generate a personalised pitch in seconds. Research at least 3 recent episodes first and lead with a specific angle that serves their business audience.
EMJ GOLD: Pharma news, views and analysis is hosted by EMJ. The show is categorised under business (education) and has published 321 episodes.
EMJ GOLD: Pharma news, views and analysis has published 321 episodes.
EMJ GOLD: Pharma news, views and analysis regularly covers business, education. It sits in the business category, with a education focus.
EMJ GOLD: Pharma news, views and analysis is accessible for guests with genuine business expertise. A personalised, episode-aware pitch will still outperform a generic one every time.
EMJ GOLD: Pharma news, views and analysis hasn't explicitly signalled guest openness in recent episodes. That doesn't rule out pitching. your hook just needs to be especially compelling and relevant to their recent content.
Episodes of EMJ GOLD: Pharma news, views and analysis average 13 minutes. a focused format where a clear narrative arc and tight preparation matter most.
Our data rates EMJ GOLD: Pharma news, views and analysis's guest bar at 80/100 (Premium tier). Established thought leaders with verified media credentials. Sign in to PitchCentric to see how your own Pod Score compares against this show.
Methodology. Booking Probability™ blends Listen Score, 30-day Virality, open-to-guests detection, and Apple ratings. Data refreshed every 60 minutes. Listen Score and Booking Probability are calculated by PitchCentric. Last enriched 10 days ago.